Pal SK - Search Results

1

Tivozanib in renal cell carcinoma: a new approach to previously treated disease.

Salgia NJ, Zengin ZB, Pal SK. Salgia NJ, et al. Among authors: pal sk. Ther Adv Med Oncol. 2020 May 22;12:1758835920923818. doi: 10.1177/1758835920923818. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32547647 Free PMC article. Review.

2

Renal cell carcinoma therapy in 2010: many options with little comparative data.

Pal SK, Figlin RA. Pal SK, et al. Clin Adv Hematol Oncol. 2010 Mar;8(3):191-200. Clin Adv Hematol Oncol. 2010. PMID: 20400934 Review.

3

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

Bourdeanu L, Twardowski P, Pal SK. Bourdeanu L, et al. Among authors: pal sk. Clin J Oncol Nurs. 2011 Oct;15(5):513-7. doi: 10.1188/11.CJON.513-517. Clin J Oncol Nurs. 2011. PMID: 21951737

4

Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.

Carmichael C, Lau C, Josephson DY, Pal SK. Carmichael C, et al. Among authors: pal sk. Clin Adv Hematol Oncol. 2012 May;10(5):307-14. Clin Adv Hematol Oncol. 2012. PMID: 22706540 Review.

5

Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.

Pal SK, Vogelzang NJ. Pal SK, et al. Clin Adv Hematol Oncol. 2013 Mar;11(3):146-55. Clin Adv Hematol Oncol. 2013. PMID: 23598982 Review.

6

A new age for vaccine therapy in renal cell carcinoma.

Pal SK, Hu A, Figlin RA. Pal SK, et al. Cancer J. 2013 Jul-Aug;19(4):365-70. doi: 10.1097/PPO.0b013e31829d74b4. Cancer J. 2013. PMID: 23867519 Free PMC article.

7

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP. Choueiri TK, et al. Among authors: pal sk. Ann Oncol. 2014 Aug;25(8):1603-8. doi: 10.1093/annonc/mdu184. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827131 Free PMC article. Clinical Trial.

8

Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.

Pal SK, Hu A, Chang M, Figlin RA. Pal SK, et al. Clin Adv Hematol Oncol. 2014 Feb;12(2):90-9. Clin Adv Hematol Oncol. 2014. PMID: 24892254 Review.

9

Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma.

Pham A, Ye DW, Pal S. Pham A, et al. Urol Oncol. 2015 Dec;33(12):517-27. doi: 10.1016/j.urolonc.2015.07.020. Epub 2015 Sep 5. Urol Oncol. 2015. PMID: 26351153 Review.

10

Advances in treatment of metastatic renal cell carcinoma.

Gong J, Gerendash B, Dizman N, Khan A, Pal SK. Gong J, et al. Among authors: pal sk. Curr Opin Urol. 2016 Sep;26(5):439-46. doi: 10.1097/MOU.0000000000000319. Curr Opin Urol. 2016. PMID: 27467136 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,146 results

Search Page

Filters